Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash & Current Investments (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Cash & Current Investments for 5 consecutive years, with $77.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 109.84% year-over-year to $77.8 million, compared with a TTM value of $77.8 million through Dec 2025, up 109.84%, and an annual FY2025 reading of $77.8 million, up 109.84% over the prior year.
  • Cash & Current Investments was $77.8 million for Q4 2025 at Aligos Therapeutics, down from $156.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $240.4 million in Q3 2021 and bottomed at $35.4 million in Q3 2024.
  • Average Cash & Current Investments over 5 years is $124.1 million, with a median of $109.5 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments crashed 72.68% in 2024, then soared 340.87% in 2025.
  • Year by year, Cash & Current Investments stood at $187.0 million in 2021, then crashed by 56.43% to $81.5 million in 2022, then surged by 66.71% to $135.8 million in 2023, then plummeted by 72.68% to $37.1 million in 2024, then surged by 109.84% to $77.8 million in 2025.
  • Business Quant data shows Cash & Current Investments for ALGS at $77.8 million in Q4 2025, $156.2 million in Q3 2025, and $227.2 million in Q2 2025.